SHILPA MEDICARE LIMITED

Material Risks

ESG Targets & Commitments

AI Risk Summary

# SHILPA MEDICARE LIMITED – FINANCIAL RISK SUMMARY Shilpa Medicare's largest financial exposure stems from **compliance risk (10/10 score)** and **Extended Producer Responsibility (EPR) uncertainty**, with estimated remediation costs of ₹1–3 crore annually. The company faces material regulatory jeopardy under SEBI BRSR Core Expansion mandates—non-disclosure or misstatement of environmental metrics could trigger enforcement action, stock penalties, or delisting risk for listed entities. EPR applicability remains undefined despite a 6.5/10 exposure risk, creating contingent liability uncertainty; pharmaceutical formulation waste streams typically incur ₹50–200 lakh in compliance infrastructure and reverse logistics. Immediate priority: clarify EPR applicability under Indian Extended Producer Responsibility rules and complete Scope 1/2 emissions baseline disclosure to avoid BRSR non-compliance penalties.

Source: SHILPA MEDICARE LIMITED BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.